ラマト・ガンで最高の血漿交換術医師 - トップ4名の医師

Prof. Avichai Shimoni, MD

Director, Bone Marrow Transplantation Department – Sheba Medical Center

World-Renowned Expert in Bone Marrow Transplantation & Cellular Therapy

Prof. Avichai Shimoni is a globally recognized hemato-oncologist with over 30 years of experience, specializing in bone marrow transplantation (BMT), cellular therapies, and advanced treatment of blood cancers.

As Director of the Bone Marrow Transplantation Department at Sheba Medical Center, he leads one of the most advanced and high-volume transplant programs in the region, treating patients with complex and high-risk hematologic malignancies.

Areas of Expertise

• Bone Marrow Transplantation (Core Expertise)
•  
  • Allogeneic and autologous stem cell transplants
  •  
  • Management of high-risk and relapsed disease
  •  
• Advanced Cellular Therapies
•  
  • CAR-T Cell Therapy for leukemia, lymphoma, and multiple myeloma
  • Integration of cutting-edge immunotherapy into clinical practice
  •  
• Hematologic Malignancies
• 
  Acute leukemias (AML, ALL), CLL, NHL, Hodgkin lymphoma, MDS, CML, myelofibrosis, and multiple myeloma
•  

International Training & Expertise

Prof. Shimoni completed advanced fellowship training in Bone Marrow Transplantation at MD Anderson Cancer Center, one of the world’s leading oncology institutions.

His clinical approach focuses on:

• Delivering curative therapies for complex blood cancers
• Combining transplantation with modern immunotherapy
• Personalizing treatment based on disease biology and patient condition
•  

Leadership & Academic Roles

• Director, Bone Marrow Transplantation Department, Sheba Medical Center
• Chairman, Department of Hematology, Tel Aviv University
• Professor of Hematology

Prof. Shimoni plays a key role in training future hematologists and advancing clinical research in transplantation and cellular therapy.

Research & Recognition

• Author of 250+ scientific publications
• Leading research in CAR-T therapy and stem cell transplantation
• Frequently recognized among Israel’s Best Doctors (Forbes 2025–2026)

Clinical Excellence

Prof. Shimoni is known for treating complex, high-risk cases, offering patients access to:

• Advanced transplant techniques
• Innovative cellular therapies
• Multidisciplinary, highly coordinated care

His work bridges clinical practice and research, ensuring patients benefit from the latest medical advancements.

Patient-Centered Approach

Prof. Shimoni provides highly specialized, personalized care, focusing on:

• Achieving the best possible clinical outcomes
• Offering curative treatment options whenever possible
• Supporting patients throughout complex treatment journeys
•  

A Global Leader in Advanced Hemato-Oncology

Through his leadership in bone marrow transplantation and CAR-T therapy, Prof. Shimoni offers patients access to one of the most advanced and comprehensive blood cancer treatment programs worldwide.

Dr. Abraham Avigdor, MD

Director, Institute of Hematology & Co-Director, Hematology and Bone Marrow Transplantation Division – Sheba Medical Center

Global Leader in Lymphoma, CAR-T Therapy & Advanced Hemato-Oncology

Dr. Abraham Avigdor is a highly distinguished hemato-oncologist with over 35 years of experience, specializing in the treatment of lymphomas, multiple myeloma, and complex blood cancers.

As Director of the Institute of Hematology at Sheba Medical Center, he leads one of the region’s most advanced programs in bone marrow transplantation and cellular therapies, including CAR-T treatment.

Areas of Expertise

• Lymphoma (Primary Focus)
• 
  Expert in all types of lymphoma, including Hodgkin and Non-Hodgkin lymphoma
• Advanced Hemato-Oncology Treatments
•  
  • CAR-T Cell Therapy – pioneer in integrating CAR-T into lymphoma and myeloma treatment
  •  
  • Bone Marrow Transplantation – both autologous and allogeneic transplants
  •  
  • Stem Cell Therapies and advanced cellular treatments
  •  
• Multiple Myeloma
  Personalized and innovative treatment strategies for complex cases
•  
• Precision Diagnostics
  Use of PET/CT imaging as a prognostic tool and integration of biological and immunological therapies
•  

Clinical Leadership & Innovation

Dr. Avigdor is internationally recognized for advancing modern lymphoma care, focusing on:

• Integration of immunotherapy and targeted treatments
• Development of innovative treatment protocols
• Personalized, data-driven patient management

His work has helped shape the use of CAR-T therapy as a standard option in advanced hematologic cancers.

International Research & Collaboration

Dr. Avigdor collaborates with leading global research groups, including:

• LYSA (France) – Lymphoma Study Association
• European Mantle Cell Lymphoma Network (EMCL)
• International PET Study Groups in Lymphoma & Myeloma

He has authored 130+ scientific publications, contributing significantly to advancements in lymphoma treatment and cellular therapies.

Leadership & Academic Roles

• Director, Institute of Hematology, Sheba Medical Center
• Co-Director, Hematology & Bone Marrow Transplant Division
• Founder & President, Israeli Lymphoma Working Group
• Former Chairman, Israeli Lymphoma Study Group (2011–2018)
• Senior Lecturer, Tel Aviv University
• Member, National Hematology Consultation Committee (Health Basket)
•  

Education & Training

• MD, Ben-Gurion University of the Negev
• Residency in Internal Medicine & Hematology, Sheba Medical Center
• Postdoctoral Fellowship in Stem Cell Biology, Weizmann Institute of Science

Awards & Recognition

• Knesset Prize for excellence in medical studies
• Israeli Ministry of Health Award for outstanding physician performance
• Sackler Prize for Research Excellence, Tel Aviv University

Patient-Centered Approach

Dr. Avigdor combines decades of experience, global leadership, and cutting-edge therapies to provide highly personalized care for patients with complex blood cancers.

His approach focuses on:

• Access to the most advanced treatments worldwide
• Multidisciplinary care and precise diagnosis
• Improving survival while maintaining quality of life
•  

A Leading Name in Modern Hemato-Oncology

Through his leadership in CAR-T therapy, bone marrow transplantation, and lymphoma research, Dr. Avigdor offers patients access to one of the most advanced and comprehensive blood cancer programs globally.

Jair Bar, MD, PhD, Professor

Thoracic Oncologist | Deputy Director of Cancer Center | Lung Cancer Specialist

Areas of Expertise

Professor Jair Bar specializes in thoracic oncology, with a strong focus on advanced lung cancer treatment and translational research:

Lung Cancer (non-small cell and advanced stages)

Thoracic Oncology

Medical Oncology & Radiotherapy

Molecular Biology & Genetics in Cancer

Immunotherapy and Resistance Mechanisms

Translational Oncology Research

About the Doctor

Professor Jair Bar is a leading thoracic oncologist and serves as the Deputy Director of the Cancer Center at Sheba Medical Center.

He also heads the Thoracic Oncology Unit, where he focuses on the treatment of lung cancer using advanced systemic therapies, including immunotherapy and targeted treatments.

In addition to his clinical work, Prof. Bar leads a research laboratory dedicated to studying resistance to immunotherapy, contributing to the development of more effective cancer treatment strategies.

He combines clinical expertise with cutting-edge research, ensuring that patients benefit from the most up-to-date therapeutic approaches.

Clinical Approach

Personalized cancer treatment based on molecular and genetic profiling

Integration of immunotherapy, targeted therapy, and radiotherapy

Multidisciplinary decision-making for complex cases

Focus on improving survival outcomes and quality of life

Positions

Deputy Director, Cancer Center, Sheba Medical Center

Head of Thoracic Oncology Unit

Chair, Israel Lung Cancer Group (since 2003)

Senior Lecturer, Tel Aviv University

Professional Memberships

Member of Israel Society of Clinical Oncology and Radiotherapy

Member of American Society of Clinical Oncology

Member of American Association for Cancer Research

Education and Training

MD, Hebrew University of Jerusalem (Hadassah Medical School)

PhD in Molecular Biology, Weizmann Institute of Science

Board Certifications

Medical Oncology

Radiotherapy Oncology

Research & Publications

Professor Bar is actively involved in translational and clinical research, with publications focused on lung cancer biology and treatment, including:

Cancer metabolism in lung cancer based on exhaled breath analysis

Angiogenesis inhibition strategies in lung cancer therapy

He continues to contribute to advancing precision oncology and immunotherapy approaches in thoracic cancers.

Dr. Hila Magen, MD

Head, Multiple Myeloma & Amyloidosis Unit – Sheba Medical Center

Leading Expert in Multiple Myeloma, Amyloidosis & Advanced Cellular Therapies

Dr. Hila Magen is a distinguished hemato-oncologist with over 35 years of experience, recognized as one of Israel’s leading experts in the treatment of multiple myeloma and complex plasma cell disorders.

As Head of the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center, she leads a highly specialized program focused on advanced, personalized therapies, including CAR-T cell treatment for high-risk patients.

Areas of Expertise

• Multiple Myeloma (Primary Focus)
• 
  Comprehensive management of relapsed, refractory, and high-risk myeloma
• Amyloidosis & Plasma Cell Disorders
  Advanced diagnosis and tailored treatment strategies
•  
• Advanced Cellular Therapies
•  
  • CAR-T Cell Therapy – principal investigator in innovative, point-of-care CAR-T programs
  • Integration of cutting-edge immunotherapies into clinical care
  •  
• Hematologic Malignancies
• 
  Lymphomas and complex blood disorders requiring precision treatment
•  

Clinical Leadership & Innovation

Dr. Magen leads one of the region’s most advanced units dedicated to myeloma and amyloidosis, focusing on:

• Personalized, targeted therapies
• Early access to innovative treatments and clinical trials
• Improving long-term outcomes and quality of life

She is actively involved in developing next-generation CAR-T therapies, offering patients access to some of the most advanced treatment options available worldwide.

International Training & Expertise

Dr. Magen completed advanced training at leading global institutions:

• Fellowship in Multiple Myeloma – University of Arkansas for Medical Sciences
• Fellowship in Lymphocytic Leukemia – MD Anderson Cancer Center

Leadership & Academic Roles

• Head, Multiple Myeloma & Amyloidosis Unit, Sheba Medical Center
• Instructor, Tel Aviv University
• Active contributor and speaker at international hematology conferences

Research & Recognition

• Author of 100+ scientific publications
• Contributor to landmark clinical studies in multiple myeloma treatment
• Active reviewer in international medical journals
•  

Clinical Approach

Dr. Magen is known for delivering highly personalized and innovative care, focusing on:

• Precision diagnosis and tailored treatment plans
• Combining standard therapies with cutting-edge innovations
• Supporting patients through complex, long-term treatment journeys

Patient-Centered Care

Dr. Magen provides compassionate, expert care, helping patients navigate complex diagnoses with access to world-class treatments, advanced technologies, and multidisciplinary support.

A Leader in Modern Myeloma Treatment

Through her leadership in CAR-T therapy, precision medicine, and advanced myeloma care, Dr. Magen offers patients access to one of the most specialized and advanced treatment programs globally.